How much does tirzepatide cost? Brand vs compounded

How much does tirzepatide cost?

Anywhere from about $25 to over $1,000 a month — and the honest answer is that it depends on two things: whether you take the brand or a compounded version, and what your insurance does with it. Brand tirzepatide (sold as Mounjaro and Zepbound) lists around $1,000–$1,080 a month (⚠ verify), but list price is a number almost nobody pays. With a commercial plan that covers it, the manufacturer savings card can cut that to $25; with no coverage, Lilly’s self-pay vials run roughly $349–$499; and compounded tirzepatide from a telehealth pharmacy has quoted lower still, in a legal grey zone we cover below.

Why the huge spread? Tirzepatide is the molecule, not a single product — the price attaches to whichever brand you’re prescribed, and US drug pricing stacks a sticker price on top of rebates, plan negotiations, and manufacturer programs. So “what does tirzepatide cost” has no single answer, only your answer. The rest of this page walks each route: brand, compounded, cash-pay, and insured.

Brand tirzepatide prices

Brand tirzepatide comes in two boxes with the same molecule inside. Mounjaro carries the type 2 diabetes label; Zepbound carries the weight-loss and sleep-apnea labels. Same drug, same 2.5–15 mg dosing — different label, and sometimes different coverage.

Both list in the same four-figure neighborhood, and both have manufacturer savings programs run through LillyDirect, Lilly’s direct-to-patient pharmacy channel. The key difference for cash payers: Lilly currently sells discounted single-dose Zepbound vials self-pay, but there’s no equivalent self-pay vial program on the Mounjaro side — Mounjaro’s discount runs through the savings card, which needs commercial insurance (⚠ verify current programs).

Because the two brands are the same drug, the full coverage breakdowns live on the brand pages: Mounjaro cost for the diabetes-coverage path, and Zepbound cost for weight-loss coverage plus the self-pay vial program.

Compounded tirzepatide cost

Compounded tirzepatide is a pharmacy-mixed version of the same active ingredient, usually supplied in a multi-dose vial and drawn with a syringe. Through telehealth channels it has typically run well below brand price — commonly quoted in the low-hundreds-per-month range (⚠ verify — this is a competitor-observed range, not a manufacturer figure, and it varies by seller). It’s cheaper because it skips brand pricing, patent economics, and the manufacturer’s supply chain entirely.

That price comes with caveats that aren’t optional reading:

• The shortage ended. Mass compounding was legal mainly because tirzepatide was on the FDA’s drug-shortage list. The FDA declared that shortage resolved in 2024, which removed the main legal basis for it, and Eli Lilly has actively sued sellers of compounded copies (⚠ verify current enforcement status).
• It’s not FDA-reviewed. Compounded tirzepatide isn’t checked for dose, purity, effectiveness, or quality, and those can vary between sellers. A quoted price is not evidence the product is legal or verified.
• The trial numbers don’t transfer. The strong weight-loss figures (like ~21% in SURMOUNT-1) come from FDA-approved brand tirzepatide, not compounded versions.

Tirzepatide cost without insurance

If you’re paying cash and want brand-name product, don’t walk the prescription into a regular pharmacy — that’s the ~$1,080 route. The cash-pay options, ranked cheapest-realistic first:

1. Lilly self-pay Zepbound vials. Sold direct through LillyDirect at roughly $349–$499 a month, tiered by dose (⚠ verify tiers). You still need a valid prescription, but no insurance is billed and no prior authorization applies. This is usually the cheapest legitimate, FDA-approved brand route for the uninsured. Note the fine print: the discounted price has historically depended on refilling within a set window (⚠ verify current rule).
2. Compounded tirzepatide. Often quotes lower than the self-pay vials, but trades the FDA’s dose-and-purity guarantee — and post-shortage legal footing — for that discount. See the section above and the full compounded guide.
3. Manufacturer savings card, not-covered price. If you have commercial insurance that simply doesn’t cover tirzepatide, the savings card has historically still knocked list down to around $550–$650/mo (⚠ verify). Worse than self-pay vials, but relevant if you’re on Mounjaro rather than Zepbound.
4. Pharmacy discount cards. GoodRx-style cards shave something off the retail counter price, and prices swing between pharmacies in the same zip code — worth a check, though rarely competitive with the self-pay vial program on brand tirzepatide.

Don’t wait for a generic to bail you out. There isn’t one, and there won’t be for years — anything marketed as “generic tirzepatide” is a scam signal, not a route.

Tirzepatide cost with insurance

With insurance, the single biggest variable is why it’s prescribed — because the same molecule is covered very differently depending on the label. Mounjaro for type 2 diabetes is a covered benefit on many plans; Zepbound for weight loss runs into the weight-loss-drug exclusion that a lot of employer plans still carry. Same drug, different answer, entirely because of the diagnosis on the prescription.

Even when it’s covered, expect prior authorization: your prescriber documents your diagnosis, BMI, weight-related conditions, and sometimes prior treatments tried. Weight-loss coverage in particular often adds hoops that the diabetes indication doesn’t. Once approved, copays commonly land anywhere from $25 (savings card stacked on decent coverage) to a few hundred a month, depending on your plan’s tier placement (⚠ verify).

If you’re denied, appeal — the denial letter must state a reason, and a letter of medical necessity from your prescriber addressing that exact reason overturns a meaningful share of denials. Before you assume the worst, check your actual formulary rather than guessing.

On the government side: Medicare Part D has long excluded drugs prescribed for weight loss, though it can cover tirzepatide for a medical indication like type 2 diabetes (as Mounjaro). A 2026 coverage expansion opens a path for some Part D plans to cover it with copays around $50 a month (⚠ verify — which plans and eligibility are still settling). The manufacturer savings card never applies to Medicare, Medicaid, or any government plan — that’s federal law, not Lilly policy.

Ways to bring the cost down

The realistic levers, in rough order of impact:

1. Run the numbers before you commit. Coverage, dose, and route interact in ways that are hard to eyeball. The GLP-1 cost calculator compares brand, self-pay, and savings-card totals for your situation.
2. Match the brand to your coverage. If you have diabetes, the Mounjaro path may be covered where Zepbound isn’t. Get the savings card for your brand — the Zepbound coupon page walks the weight-loss side.
3. Use Lilly’s self-pay vials if you’re uninsured. The ~$349–$499 Zepbound route beats the not-covered savings-card price by hundreds a month (⚠ verify).
4. Appeal a denial. A letter of medical necessity is genuinely a pricing strategy, especially on the weight-loss side. Your prescriber writes it, and their letter carries more weight than anything you send yourself. The insurance checker walks the coverage rules first.
5. Spend pre-tax dollars. FSA/HSA funds apply to brand prescriptions — an effective 20–35% discount depending on your tax bracket (⚠ verify framing).
6. Understand compounded before chasing the lowest quote. Cheaper on the sticker, murkier everywhere else. Read the compounded guide so a low price doesn’t become an expensive mistake.

One last variable: on the self-pay vial route, your dose sets your price, since tiers step up with strength. Where you land on the titration ladder has a direct line to your monthly bill — the tirzepatide dosage guide walks that ladder.